Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In light of the COVID-19 pandemic, this World View highlights the need to revolutionize current cancer research practices in terms of animal models and the collection and distribution of patient samples, in order to avoid history repeating itself in future pandemics.
Chen et al. find that arsenic trioxide (ATO), an FDA-approved agent for acute promyelocytic leukaemia, can rescue common p53 structural mutants and restore p53 function.
Bartok, Pataskar, Nagel et al. show that long-term interferon γ-induced tryptophan degradation interferes with mRNA translation in melanoma. They reveal a mechanism by which indoleamine 2,3-dioxygenase 1 and amino acid starvation-dependent ribosomal frameshifting leads to immunogenic aberrant peptide presentation.
Yu and Green et al. describe a novel mechanism of systemic immunosuppression by liver metastases, whereby intrahepatic myeloid cells induce apoptosis of activated, tumour-specific T cells.
This Review outlines the major advances that have been made to the efficacy and safety of chimeric antigen receptor (CAR) T cell therapies over the past 3 years and looks to new findings that will have consequences for the future of this immunotherapy.
This Review describes the metabolic rewiring that occurs in cancer cells transitioning through the metastatic cascade and discusses the evidence for metabolically distinct features of primary tumours and metastases.
Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in the escape from antitumour immunity in multiple malignancies. This Review discusses the mechanisms by which this signalling affects antitumour immune responses and the potential application of immune-genome precision medicine in this context.
The number of publications on deep learning for cancer diagnostics is rapidly increasing, but clinical translation is slow. This Perspective advocates performance estimation in external cohorts and strongly advises that a primary analysis is predefined in a standardized protocol preferentially stored in an online repository.
